To this aim we performed an unplanned exploratory analysis evaluating hematopoietic dynamics in the unique model of WAS patients who received, under the same treatment scheme, CD34+ cells derived from either BM or MPB transduced with same vector and in vitro transduction protocol. This evidence concerns the gene CD34 and Wiskott-Aldrich syndrome.